Nbw Capital LLC Blueprint Medicines Corp Transaction History

Nbw Capital LLC

$510 Million
Q3 2024

A detailed history of Nbw Capital LLC transactions in Blueprint Medicines Corp stock. As of the latest transaction made, Nbw Capital LLC holds 35,065 shares of BPMC stock, worth $3.38 Million. This represents 0.64% of its overall portfolio holdings.

Number of Shares

35,065

Previous 51,030 31.29%

Holding current value

$3.38 Million

Previous $5.5 Million 41.05%

% of portfolio

0.64%

Previous 1.1%

30 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 04, 2024	SELL	$84.1 - $120.5 $1.34 Million - $1.92 Million	-15,965 Reduced 31.29%	35,065 $3.24 Million
Q2 2024 Aug 14, 2024	BUY	$85.18 - $108.78 $7,325 - $9,355	86 Added 0.17%	51,030 $5.5 Million
Q1 2024 Jun 13, 2024	SELL	$73.17 - $99.79 $131,047 - $178,723	-1,791 Reduced 3.4%	50,944 $4.83 Million
Q4 2023 Jan 31, 2024	SELL	$43.96 - $92.84 $54,422 - $114,935	-1,238 Reduced 2.29%	52,735 $4.86 Million
Q3 2023 Nov 14, 2023	BUY	$46.9 - $66.0 $67,207 - $94,578	1,433 Added 2.73%	53,973 $2.71 Million
Q2 2023 Aug 15, 2023	SELL	$42.2 - $66.37 $44,605 - $70,153	-1,057 Reduced 1.97%	52,540 $3.32 Million
Q1 2023 May 11, 2023	BUY	$37.97 - $50.0 $1.25 Million - $1.65 Million	33,009 Added 160.33%	53,597 $2.41 Million
Q4 2022 Feb 14, 2023	SELL	$41.06 - $66.48 $608,427 - $985,100	-14,818 Reduced 41.85%	20,588 $901,000
Q3 2022 Nov 03, 2022	SELL	$49.93 - $77.7 $26,912 - $41,880	-539 Reduced 1.5%	35,406 $2.33 Million
Q2 2022 Aug 01, 2022	BUY	$45.23 - $70.15 $289,562 - $449,100	6,402 Added 21.67%	35,945 $1.82 Million
Q1 2022 May 04, 2022	SELL	$54.1 - $110.08 $12,497 - $25,428	-231 Reduced 0.78%	29,543 $1.89 Million
Q4 2021 Feb 03, 2022	BUY	$94.25 - $115.99 $242,976 - $299,022	2,578 Added 9.48%	29,774 $3.19 Million
Q3 2021 Nov 03, 2021	SELL	$80.98 - $109.47 $21,621 - $29,228	-267 Reduced 0.97%	27,196 $2.8 Million
Q2 2021 Aug 16, 2021	BUY	$82.78 - $101.0 $21,108 - $25,755	255 Added 0.94%	27,463 $2.42 Million
Q1 2021 May 05, 2021	BUY	$90.71 - $108.28 $141,689 - $169,133	1,562 Added 6.09%	27,208 $2.65 Million
Q4 2020 Feb 09, 2021	SELL	$92.08 - $124.48 $208,192 - $281,449	-2,261 Reduced 8.1%	25,646 $2.88 Million
Q3 2020 Nov 05, 2020	BUY	$66.45 - $92.7 $56,814 - $79,258	855 Added 3.16%	27,907 $2.59 Million
Q2 2020 Aug 07, 2020	BUY	$57.09 - $79.27 $223,336 - $310,104	3,912 Added 16.91%	27,052 $2.11 Million
Q1 2020 May 11, 2020	SELL	$48.11 - $82.22 $68,604 - $117,245	-1,426 Reduced 5.8%	23,140 $1.35 Million
Q4 2019 Feb 18, 2020	BUY	$66.73 - $82.59 $25,891 - $32,044	388 Added 1.6%	24,566 $1.97 Million
Q3 2019 Nov 04, 2019	SELL	$72.9 - $101.41 $69,692 - $96,947	-956 Reduced 3.8%	24,178 $1.78 Million
Q2 2019 Aug 05, 2019	SELL	$73.54 - $97.8 $31,180 - $41,467	-424 Reduced 1.66%	25,134 $2.37 Million
Q1 2019 May 13, 2019	BUY	$48.7 - $86.6 $5,844 - $10,392	120 Added 0.47%	25,558 $2.05 Million
Q4 2018 Feb 11, 2019	BUY	$45.57 - $74.26 $3,463 - $5,643	76 Added 0.3%	25,438 $1.37 Million
Q3 2018 Nov 14, 2018	BUY	$58.91 - $78.32 $265,801 - $353,379	4,512 Added 21.64%	25,362 $1.98 Million
Q2 2018 Aug 14, 2018	BUY	$60.96 - $101.18 $220,004 - $365,158	3,609 Added 20.93%	20,850 $1.32 Million
Q1 2018 May 07, 2018	SELL	$73.28 - $102.95 $559,932 - $786,640	-7,641 Reduced 30.71%	17,241 $1.58 Million
Q4 2017 Feb 14, 2018	SELL	$62.91 - $88.32 $280,138 - $393,288	-4,453 Reduced 15.18%	24,882 $0
Q3 2017 Nov 14, 2017	SELL	$42.37 - $69.67 $225,111 - $370,156	-5,313 Reduced 15.33%	29,335 $2.04 Million
Q2 2017 Aug 15, 2017	BUY	N/A	34,648	34,648 $1.76 Million

Others Institutions Holding BPMC

# of Institutions

352

Shares Held

60.3M

Call Options Held

2.25M

Put Options Held

1.18M

View Full List

About Blueprint Medicines Corp

Ticker BPMC
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,719,600
Market Cap $5.76B
Description
Blueprint Medicines Corporation, a precision therapy company, develops medicines for genomically defined cancers and blood disorders in the United States and internationally. The company is developing AYVAKIT for the treatment of systemic mastocytosis (SM) and gastrointestinal stromal tumors; BLU-263, an orally available, potent, and KIT inhibit...

More about BPMC

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Nbw Capital LLC, based on Form 13F filings with the SEC.

News

Stay updated on Nbw Capital LLC with notifications on news.

Account